12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telotristat etiprate: Additional Phase II data

An open-label, dose escalation, European Phase II trial in 15 patients with metastatic carcinoid syndrome who were refractory or intolerable to somatostatin analog therapy showed that thrice-daily telotristat etiprate produced a significant median reduction of 46.4% in the number of bowel movements at week 12 compared to baseline, the primary efficacy endpoint (p<0.001). Lexicon said that the number of daily bowel movements steadily decreased over time. On secondary endpoints, 75% of patients reported an improvement in relief of carcinoid symptoms at week 12. Additionally, telotristat...

Read the full 402 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >